| New budget test puts UK on front line in global drug price fight | | | LONDON (Reuters) - Can society afford modern medicines? It's a question facing governments worldwide and nowhere more so than in Britain, where a new budget test due to take effect on April 1 threatens to throw up another hurdle to patients getting the drugs. |
| |
| Mylan underpayment on EpiPen could exceed proposed settlement -study | | | NEW YORK (Reuters) - The amount that drugmaker Mylan NV avoided paying the U.S. government in Medicaid rebates for its EpiPen emergency allergy treatment since 2007 likely exceeds a proposed $465 million settlement the company announced in October, according to a study by private drug pricing experts published on Monday. |
| |
| WHO demands access to Syria's east Ghouta to bring medical aid | | | GENEVA (Reuters) - The health situation is deteriorating in Syria's eastern Ghouta region near Damascus, where 300,000 people are besieged and none of the three hospitals is functioning, the World Health Organization said on Monday in a call for access to deliver aid. |
| |
| Gilead hepatitis C drug patent faces European challenge | | | LONDON (Reuters) - International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences' hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment. |
| |
| Most states don't require lifesaving heart device in schools | | | (Reuters Health) - Automated external defibrillators (AEDs) are used to restart hearts after cardiac arrest and restore normal heartbeats, but a new study found only about one-third of U.S. states require schools to have the life-saving devices. |
| |
| | |
